Growth of solid tumor metastases is critically dependent on angiogenesis. We hypothesized that an "angiogenic-rich" milieu, as in pneumonectomy-induced lung growth, would be conducive to growth of pulmonary metastases, and that transfer of an antiangio- 
retical possibility that when pneumonectomy is used for removal of lung tumors, the availability of space signals the remaining lung to grow (2) (3) (4) (5) (6) (7) (8) (10) (11) (12) (13) (14) . In this context, conventional therapy for many forms of tumors metastatic to the lung includes surgery to remove metastatic lesions identified by imaging and/or palpation at the time of surgery (15) (16) (17) . Whereas the surgery is curative in some instances, recurrence of metastatic lesions within the lung are common (18) . Although the signals controlling the growth of metastatic tumors are undoubtedly complex, there is indirect evidence that lung metastases may grow more rapidly after pneumonectomy (19) (20) (21) .
Because the growth of new blood vessels is inherent to the growth of the lung, if the remaining lung does grow after pneumonectomy, the molecular signals involved must include mediators that induce angiogenesis. In fact, increased levels of angiogenic factors, such as insulin-like growth factor, hepatocyte growth factor, and erythropoietin, are found in models of lung growth, including postpneumonectomy compensatory growth, resulting in an "angiogenic milieu" (22) (23) (24) (25) (26) (27) (28) (29) (30) . In the context of the growth of metastases, angiogenic mediators are particularly dangerous, because the process of neoangiogenesis within growing tumors uses similar mediators as does neoangiogenesis participating in the growth of normal tissue (13, 14, (31) (32) (33) .
In the context of these considerations, we hypothesized that tumor cells metastatic to the lung will grow more rapidly in the milieu of postpneumonectomy lung growth, and that metastases growing in the lung parenchyma remaining after pneumonectomy must require proangiogenic signals for their growth. To assess these concepts, we have compared the growth of colon carcinoma metastatic to the lung in normal lung to that in the postpneumonectomy lung, and the ability of antiangiogenic therapy to suppress the growth of these tumors.
MATERIALS AND METHODS

Cells
CT26 is an undifferentiated colon adenocarcinoma cell line (H-2 d) that was derived by administration of N-nitroso-N-methylurethane to a male BALB/c mouse. CT26.CL25 was derived from CT26 cells modified to express the Escherichia coli ␤-galactosidase (␤gal) gene (kindly provided by N. P. Restifo, National Cancer Institute, Bethesda, MD) (34) . This cell line was maintained in complete RPMI 1640 medium supplemented with 10% heat-inactivated FBS (Life Technologies, Grand Island, NY), 400 g/ml G418 (Life Technologies), 2 mM glutamine, 100 g/ml streptomycin sulfate, and 100 U/ml penicillin G.
Adenovirus Vectors
The replication-deficient adenovirus vectors used in this study are based on human adenovirus type 5 genome with E1 and E3 deletions and the expression cassette in the E1 region. Adsflt expresses a naturally occurring, soluble, secreted form of the human flt-1 receptor, under control of the constitutive cytomegalovirus early/immediate promotor/ enhancer (35) . AdNull has no transgene, and is used as a control (36) . Both Ad vectors were propagated in 293 cells, purified by two rounds of cesium chloride density gradient centrifugation, dialyzed, titered by plaque-forming assay on 293 cells, and demonstrated to be free of replication-competent adenoviruses (37) (38) (39) .
Experimental Model
Male BALB/c (H-2 d) mice, 6-8 wk old, were obtained from Taconic (Germantown, NY). Animals were housed under specific pathogenfree conditions and treated according to National Institutes of Health Guidelines.
To carry out unilatereral left pneumonectomy, mice were anesthetized with a combination of ketamine (100 mg/kg) and xylazine (10 mg/kg) by intraperitoneal injection. The trachea was cannulated with a 22-gauge angiocatheter (Becton Dickenson, Franklin Lakes, NJ) and mechanical ventilation was achieved via a small animal ventilator (Harvard Apparatus Inc., Holliston, MA). After a left thoracotomy in the third intercostal space, the left mainstem bronchus was carefully isolated and tied at the hilum with silk suture, followed by cutting distal to the ligation for removal of the left lung. The chest and skin were closed and mechanical ventilation was discontinued as spontaneous respiration was observed, and the animals were extubated. Mice in the sham groups underwent left thoracotomy in the same fashion, and the chest was closed without pneumonectomy. At the appropriate time points, mice were anesthetized and killed with a lethal dose of ketamine/ xylazine, and the right lungs were removed and assessed as described subsequently here.
A metastatic lung tumor model was established by injecting 3 ϫ 10 5 CT26.CL25 tumor cells in 100 l of PBS (pH 7.4) via the jugular vein of syngeneic BALB/c mice. To characterize the time course of lung metastasis growth to optimize the Adsflt treatment and evaluation schedule, mice were killed 6, 9, 12, and 14 d after tumor injection. At each time point, lungs of one group (n ϭ 5) were harvested, and lung wet and dry weight was measured as described subsequently here. In the other group (n ϭ 5), lungs were weighed and ␤gal activity of the lungs was quantified.
To assess the effect of compensatory lung growth after pneumonectomy on the growth of lung metastases, the 3 ϫ 10 5 CT26.CL25 tumor cells in 100 l of PBS were administered via the jugular vein of syngeneic BALB/c mice. Mice received left pneumonectomy or sham operation 14, 7, 4, or 1 d before tumor injection or 4, 2, or 1 d after tumor injection (5 mice per group for each time point). Twelve days after tumor injection, lungs were harvested, weighed, homogenized with lysis solution, and ␤gal activity was measured and adjusted for total protein.
Quantification of Lung Growth with and without Metastases
Overall lung growth with and without metastases was determined by quantification of lung weight (right lung in the pneumonectomy group; right and left lungs separately in the sham group) and by quantification of lung ␤gal activity (35, 40) . Lungs were harvested en bloc and dissected away from the heart and thymus. The lungs were immediately weighed (wet weight) and then placed in a desiccating oven at 65ЊC for 48 h to measure dry weight. The ratio of wet/dry weight was used to quantify lung water content. The ␤gal reporter gene in the CT26.CL25 colon carcinoma cells was assessed in lung lysates in a luminometer using Galacto-Light Plus kit (Tropic Inc., Bedford, MA). ␤gal activity in the lung was expressed as total activity/lung and relative to total lung protein determined using the BCA assay (Bio-Rad Laboratories, Hercules, CA).
Histology
To assess the morphology of the lung, the lungs were fixed with 4% paraformaldehyde and embedded in paraffin. Butterfly-shaped sections of 5 m thickness were cut and stained with hematoxylin-eosin (H&E; American Histoserve, Gaithersburg, MD).
Treatment of Lung Metastasis
To assess the effect of antiangogenic therapy with soluble flt-1 on the compensatory growth of the contralateral lung after pneumonectomy without tumor, Adsflt (5 ϫ 10 8 plaque-forming units [pfu]) was administered intratracheally to mice after pneumonectomy; the same volume of PBS was administered as control (n ϭ 5 mice). Lung wet weight was measured on Day 7. As a positive control for the Adsflt vector, studies were performed in mice with pre-established lung metastases as previously described (35) . Metastatic lung tumors were established by injecting 3 ϫ 10 5 CT26.CL25 tumor cells in 100 l of PBS through the jugular vein of syngeneic BALB/c mice. The day after injecting tumor cells, mice were administered 5 ϫ 10 8 pfu of AdNull in 50 l of PBS through the intranasal route, or 5 ϫ 10 8 pfu of Adsflt by the intravenous or intranasal routes (all groups, n ϭ 5 mice). For intranasal administration, the mice were anesthetized, restrained, and placed on an operating surface at an angle of 60Њ. The Adsflt or AdNull vectors (5 ϫ 10 8 pfu) resuspended in 50 l of PBS were administered drop-wise into the nasal passages with an insulin syringe and 27-gauge needle over a period of 20-30 min per animal. Animals were killed 12 d after tumor cell injection. To quantify the tumor growth, lungs were weighed and ␤gal activity of the lungs was measured (35, 40) .
To assess the ability of Adsflt vector delivered to growing lung to suppress the accelerated lung metastatic tumor growth following unilateral pneumonectomy, 3 ϫ 10 5 CT26.CL25 tumor cells in 100 l of PBS were administered via the jugular vein of syngeneic BALB/c mice 1 d after left pneumonectomy or sham operation. One day after injecting tumor cells, mice were administered 5 ϫ 10 8 pfu of Adsflt, AdNull, or no vector in 50 l of PBS by the intranasal route, or 5 ϫ 10 8 pfu of Adsflt in 100 l of PBS by the intravenous route (5-6 mice per group). Animals were killed 12 d after tumor injection. To quantify the tumor growth, lungs were weighed, and ␤gal activity of the lungs was measured as described previously here.
Statistical Analysis
All data are reported as mean Ϯ SE. Statistical evaluation was performed with the two-tailed Student's t test. Correlations were assessed by linear regression analysis using StatView 5.0 (SAS Institute, Cary, NC).
RESULTS
Compensatory Lung Growth after Left Pneumonectomy
Compensatory lung growth after left pneumonectomy in BALB/ c mice was confirmed by measuring right lung wet weight. Postpneumonectomy right lung mass showed rapid growth, and increased by 30% at Day 5 (P Ͻ 0.0005), 45% at Day 7 (P Ͻ 0.0002), and 49% at Day 14 (P Ͻ 0.0001) compared with right lung wet weight in the sham surgery group (Figure 1 ). These observations demonstrate that left pneumonectomy leads to a rapid and complete compensatory lung growth response in the remaining lung, sufficient to restore normal mass by 14 d after surgery, with most of the lung growth occurring within the first 7 d. This compensatory lung growth was not suppressed significantly by intratracheal administration of Adsflt (lung wet weight in pneumonectomy with Adsflt was 127.9 Ϯ 12.6 mg, compared with 130 Ϯ 8.7 mg in pneumonectomy with PBS; P Ͼ 0.1).
Lung Metastases Model
In the context of lung metastases, postpneumonectomy lung growth was associated with enhanced tumor growth in the lung (Figure 2 ). The assessment was on Day 12 (rather than Day 14) because mice on Day 14 had increased respiratory rates and produced pleural effusion with hemorrhage due to extended lung metastases (data not shown). Lung histology of the mice with metastases showed an increased lung mass compared with the sham surgery animals, along with an increase in the mass of the tumor (Figure 2 ). The right and left lung histology in sham- (Figure 2A ). In contrast, the right lung after pneumonectomy showed metastases greater in size and widely spread in the subpleural region ( Figure 2B ). Neither the sham lung nor the postpneumonectomy lung had significant inflammatory infiltration or lung edema, nor (in the animals with metastases) central necrosis in the tumors. Mice with lung metastases showed an increase in lung wet weight over time ( Figure 3A) . As a group, for control animals and those after pneumonectomy, comparison of lung wet weight to lung dry weight showed an excellent correlation (r 2 ϭ 0.99, P Ͻ 0.0001), demonstrating that changes in lung wet weight could be used as a valid indicator of increase of lung mass (e.g., the increase in wet weight was not secondary to edema; Figure 3B ). In this context, the lung wet/dry weight ratio maintained the same level from Day 0 as control (4. Figure 3C ]).
Enhanced Lung Metastases Associated with Postpneumonectomy Lung Growth
Quantification of lung metastases during compensatory lung growth after left pneumonectomy showed that lung metastases in the postpneumonectomy right lung markedly increased compared with lungs of mice treated with sham thoracotomy (Figure 4 Table 1 ). Likewise, ␤gal activity in the right lung of mice that received a left pneumonectomy 4 d before tumor administration was significantly greater than in sham operated mice (P Ͻ 0.05; Table 1 ). † Twelve days after tumor administration, lungs were harvested, weighed and ␤-galactosidase activity was determined, and then expressed as a ratio of right lung in the pnx group to right and left in the sham group.
‡ Lung weight was significantly greater in the pnx group compared to the sham group at timepoints Ϫ7, Ϫ4 and Ϫ1 (shown in bold, P Ͻ 0.01 in all cases).
§ ␤-galactosidase activity was significantly greater in the pnx group compared to the sham group at timepoints Ϫ4 and Ϫ1 (shown in bold, P Ͻ 0.05 in both cases). 
Inhibition of Lung Metastases by Adsflt during Postpneumonectomy Lung Growth
Pre-established lung metastases were markedly suppressed by administration of 5 ϫ 10 8 pfu of Adsflt by the intranasal or intravenous routes as compared with no vector (PBS) and AdNull groups ( Figure 5 ). The lung wet weights were markedly reduced in the Adsflt-treated mice compared with both control groups (intranasal, P Ͻ 0.005; intravenous, P Ͻ 0.0005). Likewise, ␤gal activity was markedly suppressed (intranasal, P Ͻ 0.005; intravenous, P Ͻ 0.01). The most efficient time point of gene delivery was the day after tumor injection, as compared with 2, 4, and 6 d after tumor injection, which yielded more variable results. When Adsflt was delivered intranasally 2, 4, or 6 d after tumor injections, lung weight was somewhat reduced, but did not differ significantly from the PBS or AdNull control groups. When delivered intravenously 2 or 4 d after tumor injec- tions, lung weight in the Adsflt group was 50.3% (P Ͻ 0.01) and 68.1% (P Ͻ 0.02), respectively, of lung weight in the PBS and AdNull control groups (which did not differ significantly; P Ͼ 0.5 in both cases). ␤gal activity in mice that had been administered intranasal Adsflt 2 or 4 d after tumor injections was 37.3% (P Ͻ 0.05) and 48.9% (P Ͻ 0.05), respectively, of the values in the PBS and AdNull control groups (which did not differ significantly; P Ͼ 0.2 in both cases).
Lung histology demonstrated enhanced lung metastases in mice administered PBS or AdNull intranasally after left pneumonectomy compared with sham animals (compare Figures 6B and  6C to Figure 6A ). In contrast, when Adsflt was administered either by the intranasal or the intravenous route 1 d after pneumonectomy, there was a marked suppression in the mass of metastases ( Figures 6D and 6E) . The postpneumonectomy right lung treated with Adsflt by the intranasal route showed smaller scattered metastases with minor inflammation ( Figure 6D ). The right lung treated with Adsflt by the intravenous route showed marked inhibition of perivascular metastasis without inflammatory changes ( Figure 6E ).
Quantitative analysis of lung metastases during postpneumonectomy lung growth demonstrated a marked inhibition when Adsflt was administered by intranasal or intravenous routes ( Figure 7) . Postpneumonectomy lung growth enhanced lung metastases in mice that had been administered PBS or AdNull by the intranasal route as compared with the right ϩ left lungs of sham-operated mice without any treatment (lung weight, P Ͻ 0.05; as compared with PBS and AdNull treatments ( Figure 7A ). Consistent with this observation, ␤gal activity in the postpneumonectomy right lungs of mice treated with Adsflt by the intranasal or intravenous routes also showed significant suppression compared with PBS and AdNull treatments ( Figure 7B ; P Ͻ 0.01, both routes). The changes in lung weight (P Ͼ 0.05) or ␤gal activity (P Ͼ 0.7) were similar with intranasal or intravenous treatment with Adsflt. There was a discrepancy between the measurement of lung weight and ␤gal activity (i.e., the weight was not reduced as much as the ␤gal activity after nasal administration of Adsflt; this may be secondary to mild inflammation after intranasal administration of the Ad vectors [ Figure 6 ]).
DISCUSSION
This study is based on the hypothesis that tumor cells metastatic to the lung will grow more rapidly in the milieu of postpneumonectomy lung growth. Further, because metastases growing in the lung parenchyma remaining after pneumonectomy must require proangiogenic signals for their growth, it is likely that the rapid growth of lung metastases can be suppressed in the postpneumonectomy growing lung by antiangiogenic therapy. The results support this hypothesis. First, the growth of lung metastases was enhanced in the remaining lung during postpneumonectomy lung growth. Second, in vivo administration of an adenovirus vector encoding sflt-1, a soluble form of the flt-1 kinase receptor for the angiogenic factor vascular endothelial growth factor (VEGF), was effective antiangiogenic therapy, as evidenced by marked suppression of the enhanced growth of lung metastases during the postpneumonectomy lung growth.
Compensatory Lung Growth
Compensatory lung growth after lobectomy or pneumonectomy has been reported in experimental animals and humans for over 100 yr (6, 41) . Many factors, such as stretch, oxygen concentration, blood flow, growth factors, and hormones that might potentially stimulate, modify, and/or regulate this response, have been studied (1, 4, 6, 11, 12, 26, 27, 42-49) . Recently, it has been noted that several zinc finger genes as transcriptional regulators and immediate-early genes, such as c-fos, junB, and erg-1, are expressed during the rapid phase of compensatory lung growth (22, 23, 30) . Cellular proliferation and differentiation in the remaining lung after pneumonectomy should promote tumor growth (19) . In mice, removal of the left lung, which constitutes ‫ف‬ 34% of total lung tissue, initiates compensatory growth rapid enough to restore normal total lung mass within 7-14 d (4). Although the specific mechanisms of compensatory lung growth are complex and remain incompletely understood (1, 49) , it is known that postpneumonectomy lung growth is associated with an increase in the number of blood vessels in the lung (27, 30, 48) , and thus proangiogenic factors must play a central role in postpneumonectomy lung growth. Interestingly, however, there have been no studies demonstrating a critical role of VEGF in postpneumonectomy compensatory growth. Our results, which showed no effect of Adsflt administration on compensatory growth, are consistent with the notion that alternative angiogenic factors are more critical for lung growth after pneumonectomy. The time course of transgene expression after adenovirus administration via the respiratory or intravenous routes is limited by immunity (primarily cellular) against the adenovirus vector per se. Although the intranasal route yields much higher levels of the transgene in the lung, the vascularization mechanisms of tumor growth is likely different than that of the normal lung and/or the relative numbers of VEGF receptors on the relevant endothelium may be different.
Antiangiogenic Therapy
When tumor size exceeds 1-2 mm 3 , the tumor becomes critically dependent on angiogenesis to continue growing (31, 50) . Although the process of tumor neovascularization promoted by secretion of a number of angiogenic mediators is controlled tightly by a balance of activating and inhibiting factors, VEGF plays a central role in tumor progression and metastasis (32, 33, 51, 52) . Based on the critical dependence of many tumors on VEGF, the strategy using a soluble form of the flt-1 VEGF receptor is predicted to be applicable to the treatment of many solid tumors (34, 35, 53) . Under conditions of excess soluble flt-1 protein, VEGF is prevented from binding to its cognate cell surface receptors (i.e., soluble flt-1 functions as an efficient, dominant negative inhibitor of angiogenesis in vivo [33, 54] ). Although this function might be overwhelmed by an excess of VEGF produced by the tumor cells, continuous overexpression of antiangiogenic factors by the administration of Adsflt shifts the balance in favor of antiangiogenesis within the tumor and leads to a reduction of solid tumor, including pulmonary metastases. Importantly, treatment with Adsflt markedly suppressed both established pulmonary metastases and postpneumonectomyenhanced tumor growth as well. This suggests that an antiangiogenesis strategy could be an effective component of postsurgery treatment (see subsequent discussion), but could also slow the growth rates of established tumors in the absence of surgical interventions.
Pulmonary Metastases after Pneumonectomy
Whereas most attention regarding compensatory lung growth has been focused on lung overexpansion associated with the long-term development of emphysema and deteriorating pulmonary function, the observations in the present study suggest the theoretical possibility that pulmonary resection for treatment of tumors may result in conditions that promote compensatory lung growth and are also permissive of accelerating the growth of residual tumor. Further, surgical treatment for primary lung cancer or metastatic lung tumor includes manipulation procedures that may be implicated in hematogenous micrometastasis to the remaining lung (55) . Surgery for advanced non-small cell lung cancer, such as stage IIIA or metastatic lung tumors, is controversial but curative in some instances, and may be occasionally associated with long-term survival. However, in some patients, secondary metastases and/or recurrence within the remaining lung appear soon after the first pulmonary resection (17, 20, 56) . Although the signals controlling the growth of metastatic tumors are undoubtedly complex, the data in the present study suggest indirect evidence that lung metastases may grow more rapidly during compensatory lung growth after pneumonectomy. In this context, an antiangiogenesis strategy for tumors in the remaining lung after lung surgery, such as Adsflt-mediated gene therapy, may be useful to prevent the regrowth of micrometastases. The data in the present study suggest the time point of administration of antiangiogenic agents is important, and it is likely that antiangiogenic therapy should occur near the time of surgery.
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